Furthermore, the HERNATA study demonstrated that docetaxel and trastuzumab were not superior to vinorelbine and trastuzumab in terms of efficacy in patients with HER2-positive advanced breast cancer, but patients who received vinorelbine experienced fewer grade 3 and 4 adverse events (AEs) than those treated with docetaxel [22]. The gene discussed is ERBB2; the disease is breast cancer.